STRATATECH CORPORATION – Trademark Portfolio
Entity Type: 03
STRATATECH CORPORATION holds 18 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 16 filings in this category. The portfolio also extends into Class 1 (Chemicals) across 3 Nice Classification classes. Currently, 4 trademarks are registered. Notable registered marks include NIKS, STRATATECH, and STRATAGRAFT. The owner is based in MADISON, WI.
505 SOUTH ROSA RD
MADISON, WI 53719
Showing of trademarks Trademarks
Trademark Classifications
STRATATECH CORPORATION's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does STRATATECH CORPORATION have?
STRATATECH CORPORATION has 18 U.S. trademarks filed with the USPTO. Of these, 4 registered, 13 abandoned, 1 cancelled.
What trademark classes does STRATATECH CORPORATION file in?
STRATATECH CORPORATION files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 1 (Chemicals), Class 42 (Computer & Scientific). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are STRATATECH CORPORATION's most well-known trademarks?
STRATATECH CORPORATION's registered trademark portfolio includes well-known marks such as NIKS, STRATATECH, and STRATAGRAFT. These are among 4 currently registered trademarks in the portfolio.
What is STRATATECH CORPORATION's trademark registration success rate?
STRATATECH CORPORATION has a 22% trademark registration rate, with 4 out of 18 resolved applications resulting in successful registration. Currently, 0 applications are pending review.